Primary care management of overactive bladder symptoms: evaluation and treatment.
作者信息
Itam Sarah, Singh Gurpreet
机构信息
University College London Hospitals NHS Foundation Trust, London.
Southport and Ormskirk Hospital NHS Trust, Southport.
出版信息
Br J Gen Pract. 2017 Apr;67(657):187-188. doi: 10.3399/bjgp17X690413.
Abstract
摘要
相似文献
1
Primary care management of overactive bladder symptoms: evaluation and treatment.膀胱过度活动症症状的初级保健管理：评估与治疗
Br J Gen Pract. 2017 Apr;67(657):187-188. doi: 10.3399/bjgp17X690413.
2
Frequently asked questions in the evaluation and management of overactive bladder.膀胱过度活动症评估与管理中的常见问题
J Fam Pract. 2009 Oct;58(10 Suppl):S1-11; quiz S12.
3
The management of overactive bladder syndrome.膀胱过度活动症的管理
BMJ. 2012 Apr 17;344:e2365. doi: 10.1136/bmj.e2365.
4
Overactive bladder in men: a practical approach.
Br J Gen Pract. 2018 Jun;68(671):298-299. doi: 10.3399/bjgp18X696593.
5
Overactive bladder syndrome - management and treatment options.膀胱过度活动症——管理与治疗选择
Aust Fam Physician. 2012 Nov;41(11):878-83.
6
Overactive bladder.膀胱过度活动症
Can J Urol. 2011 Apr;18 Suppl:8-13.
7
Defining the role of overactive bladder treatments in men with lower urinary tract symptoms.明确膀胱过度活动症治疗在有下尿路症状男性中的作用。
Nat Clin Pract Urol. 2007 Apr;4(4):174-5. doi: 10.1038/ncpuro0754.
8
Overactive bladder: diagnosis and management.膀胱过度活动症：诊断与管理。
Maturitas. 2012 Feb;71(2):188-93. doi: 10.1016/j.maturitas.2011.11.016. Epub 2011 Dec 23.
9
Rethinking the approach to evaluation and management of overactive bladder.
Can J Urol. 2021 Jun;28(3):10705.
10
Re: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. A. J. Wein and R. R. Rackley J Urol, suppl., 2006; 175: S5-S10.回复：膀胱过度活动症：对病理生理学、诊断及管理的深入理解。A. J. 温及R. R. 拉克利。《泌尿外科杂志》增刊，2006年；175：S5 - S10。
J Urol. 2007 Oct;178(4 Pt 1):1553; author reply 1553. doi: 10.1016/j.juro.2007.05.173. Epub 2007 Aug 16.
引用本文的文献
1
High risk of lower urinary tract symptoms in patients with irritable bowel syndrome.肠易激综合征患者存在下尿路症状的高风险。
Tech Coloproctol. 2017 Jun;21(6):433-438. doi: 10.1007/s10151-017-1653-5. Epub 2017 Jun 24.
本文引用的文献
1
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).米拉贝隆附加治疗对初始 4 周索利那新单药治疗反应不足的失禁型逼尿过度活动症患者的疗效和安全性：一项随机双盲多中心 3B 期研究（BESIDE）。
Eur Urol. 2016 Jul;70(1):136-145. doi: 10.1016/j.eururo.2016.02.030. Epub 2016 Mar 8.
2
EAU guidelines on urinary incontinence.EAU 指南：尿失禁
Eur Urol. 2011 Mar;59(3):387-400. doi: 10.1016/j.eururo.2010.11.021. Epub 2010 Nov 24.
3
An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.国际尿控协会（IUGA）/国际尿失禁学会（ICS）关于女性盆底功能障碍术语的联合报告。
Int Urogynecol J. 2010 Jan;21(1):5-26. doi: 10.1007/s00192-009-0976-9. Epub 2009 Nov 25.
4
How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.膀胱过度活动症的症状有多普遍，以及如何进行管理？一项基于人群的患病率研究。
BJU Int. 2001 Jun;87(9):760-6. doi: 10.1046/j.1464-410x.2001.02228.x.
5
Comorbidities associated with overactive bladder.与膀胱过度活动症相关的合并症。
Am J Manag Care. 2000 Jul;6(11 Suppl):S574-9.
Zotero 插件